Empresa Colombiana de Productos Veterinarios S.A. VECOL S.A.

Empresa Colombiana de Productos Veterinarios S.A. VECOL S.A., commonly known as VECOL, is a Colombian company based in Bogotá that develops, manufactures and distributes veterinary biologicals and related products for livestock, companion animals and agriculture. Its business is organized around business units (UEN, Unidades Estratégicas de Negocio) covering production animals, companion animals, agricultural and fertilizer products, and foot-and-mouth disease (aftosa) vaccines. VECOL's portfolio is centered on animal health: vaccines, including foot-and-mouth disease and rabies vaccines, and other veterinary products for cattle, pigs, poultry, aquaculture and companion animals. The company also operates an agricultural unit that supplies crop inputs and fertilizers, with a stated focus on rice cultivation in Colombia. Its aquaculture-related work includes development of autogenous vaccines, such as a bivalent autogenous vaccine for the control of streptococcosis in tilapia, developed in response to a national animal-health emergency declared by the Colombian Agricultural Institute (ICA). VECOL presents itself as a science- and health-sovereignty-oriented company. Its website highlights large-scale delivery of foot-and-mouth disease vaccine doses for Colombia's 2025 vaccination campaign, rabies vaccine doses, and a significant share of its agricultural unit's sales directed to rice crops in 2025. It also reports an alliance with SK bioscience aimed at strengthening human vaccine production capacity in Colombia, indicating an expansion beyond purely veterinary biologicals into human health manufacturing. The company communicates through public, participatory events such as "Orgullosos de ser Vecol" and publishes news on its website and social channels (Facebook, Twitter, Instagram, YouTube, LinkedIn). It recruits through a dedicated "Trabaja con nosotros" page. VECOL is headquartered in Bogotá, Colombia, and its primary market is Colombia, with a role in national animal-health campaigns and agricultural supply.

Empresa Colombiana de Productos Veterinarios S.A. VECOL S.A. is a Colombian company headquartered in Bogotá. Publicly available evidence describes it as a company in Bogotá, Colombia, and its own website presents it as an established producer of veterinary biologicals and agricultural products organized into strategic business units (UEN). The company's historical development is closely tied to Colombia's national animal-health programs, particularly the campaign against foot-and-mouth disease (aftosa). VECOL reports delivering millions of vaccine doses for the 2025 foot-and-mouth disease vaccination campaign, as well as millions of rabies vaccine doses in 2025, indicating a long-standing role in supplying vaccines for national livestock health efforts. Over time VECOL has broadened its portfolio beyond livestock vaccines. It now operates business units for production animals, companion animals, agricultural and fertilizer products, and foot-and-mouth disease vaccines. Its agricultural unit has a stated focus on rice crops in Colombia, and the company has been active in aquaculture health, developing a bivalent autogenous vaccine for the control of streptococcosis in tilapia in response to a national animal-health emergency declared by the Colombian Agricultural Institute (ICA) through Resolution 6535. More recently, VECOL has signaled an expansion into human health. Its website reports an alliance with SK bioscience intended to strengthen human vaccine production in Colombia and to boost scientific capabilities and health sovereignty. The company also maintains an active public communication program, including participatory public events such as "Orgullosos de ser Vecol" and "VECOL: resultados que inspiran, impacto que transforma," where it shares results and achievements. It publishes news through its website and social media channels and recruits through a dedicated careers page. Specific founding dates, founders, ownership structure and financial details are not provided in the available evidence and are therefore not asserted here.

• VECOL reports delivering millions of foot-and-mouth disease vaccine doses for Colombia's 2025 vaccination campaign.

• VECOL reports delivering millions of rabies vaccine doses in 2025.

• VECOL develops a bivalent autogenous vaccine for streptococcosis in tilapia in response to ICA Resolution 6535.

• VECOL announces alliance with SK bioscience to strengthen human vaccine production in Colombia.

Colombian animal-health and agricultural biologicals producer supporting national vaccination campaigns and sanitary sovereignty.

• Foot-and-mouth disease (aftosa) vaccine

  Vaccine supplied for Colombia's national foot-and-mouth disease vaccination campaign.

• Rabies vaccine

  Vaccine delivered in millions of doses in 2025.

• Bivalent autogenous vaccine for streptococcosis in tilapia

  Developed for control of streptococcosis in tilapia in response to a national animal-health emergency.

• Agricultural and fertilizer products

  Products from the agricultural business unit, with a focus on rice crops in Colombia.

1. 1Inicio - VECOLvecol.com.co
2. 2Trabaja con nosotros - VECOLvecol.com.co
3. 3Empresa Colombiana de Productos Veterinarios S.A. VECOL S.A. (Colombia) - Wikidatawikidata.org